News - OPKO Health, CNS Diseases

Filter

Current filters:

OPKO HealthCNS Diseases

Popular Filters

1 to 25 of 26 results

European neurologists expect Biogen Idec’s Tecfidera to be preferred MS drug

European neurologists expect Biogen Idec’s Tecfidera to be preferred MS drug

16-04-2014

Surveyed neurologists in France, Germany, Italy, Spain and the UK project that 16% of their diagnosed…

AubagioBiogen IdecChemistryCNS DiseasesEuropeGenzymeMajorPharmaceuticalPharmacologyPhysicianResearchSANTecfidera

US orphan designation for OPKO's longer-acting clotting Factor VIIa-CTP

US orphan designation for OPKO's longer-acting clotting Factor VIIa-CTP

03-03-2014

The US Food and Drug Administration has granted orphan drug designation to US drugmaker OPKO Health’s…

HematologyNorth AmericaOPKO HealthPharmaceuticalRare diseasesUSA

NICE asks Biogen Idec for more information on Tecfidera

NICE asks Biogen Idec for more information on Tecfidera

21-02-2014

The UK’s National Institute for Health and Care Excellence (NICE) is calling on US biotech firm Biogen…

Biogen IdecBiotechnologyCNS DiseasesRegulationTecfideraUK

Prana reports successful Phase II results in Huntington disease trial

18-02-2014

Australia-based Prana Biotechnology has announced positive results of its Reach2HD Phase II clinical…

AustraliaBiotechnologyCNS DiseasesNeurologicalPrana BiotechnologyResearch

Forest reports third quarter sales of $846.8 million beating analysts’ expectations

Forest reports third quarter sales of $846.8 million beating analysts’ expectations

21-01-2014

US drugmaker Forest Laboratories (NYSE: FRX) released its third quarter 2013/14 results today showing…

CNS DiseasesFinancialForest LaboratoriesPharmaceuticalRespiratory and PulmonaryUSA

OPKO takes 10-fold profit on sale of stake in Sorrento Therapeutics

20-12-2013

US drugmaker OPKO Health says it has completed the sale of its stake in Sorrento Therapeutics, a clinical-stage…

FinancialMergers & AcquisitionsOPKO HealthPharmaceuticalSorrento Therapeutics

OPKO Health to buy Lab Arama to expand Latin American presence

17-12-2013

Continuing on its acquisitive path, US drugmaker OPKO Health revealed that it has entered into an agreement…

Laboratorio AramaMergers & AcquisitionsOPKO HealthPharmaceuticalSouth America

Forest Laboratories announces new appointments to its executive team

16-12-2013

New York-based pharmaceutical company Forest Laboratories (NYSE: FRX) has announced new appointments…

Anti-viralsBoardroomCardio-vascularCNS DiseasesForest LaboratoriesGastro-intestinalsPharmaceuticalRespiratory and PulmonaryUSA

Sativex approved for MS in Switzerland

Sativex approved for MS in Switzerland

27-11-2013

UK-based GW Pharmaceuticals (AIM: GWP), which is focused on novel cannaboid therapeutics, has received…

AlmirallCNS DiseasesEuropeGW PharmaceuticalsPharmaceuticalRegulationSativex

Collaboration agreement between French firms Vect-Horus and AAA

20-11-2013

French biotech company Vect-Horus has signed a scientific collaboration agreement with Advanced Accelerator…

Advanced Accelerator ApplicationsBiotechnologyCNS DiseasesEuropeLicensingMergers & AcquisitionsVect-Horus

GW Pharma sees fiscal 2012/3 revenues decline, impacted by Sativex

GW Pharma sees fiscal 2012/3 revenues decline, impacted by Sativex

19-11-2013

UK-based GW Pharmaceuticals (AIM: GWP) which is focused on novel cannaboid therapeutics, has announced…

CNS DiseasesFinancialGW PharmaceuticalsPharmaceuticalSativexUK

Sanofi’s Lemtrada gets support from FDA advisory panel

Sanofi’s Lemtrada gets support from FDA advisory panel

14-11-2013

French drug major Sanofi (Euronext: SAN) has received support from a US Food and Drug Administration…

CNS DiseasesEuropeGenzymeLemtradaPharmaceuticalRegulationSanofi

OPKO makes strategic investment in biotech firm

11-10-2013

US pharma and diagnostics firm OPKO Health has agreed to make an undisclosed strategic investment in…

BiotechnologyMergers & AcquisitionsOPKO HealthPharmaceuticalZebra Biologics

Novartis MS drug Gilenya leads to reduction in brain volume drug

Novartis MS drug Gilenya leads to reduction in brain volume drug

04-10-2013

Novartis has revealed new data indicating that continued treatment with Gilenya led to a reduction in…

CNS DiseasesEuropeGilenyaNovartisPharmaceuticalResearch

Inovio reveals success in DNA plasmid technology

Inovio reveals success in DNA plasmid technology

25-09-2013

US drug developer Inovio Pharmaceuticals has demonstrated the success of its new DNA plasmid technology…

Anti-Arthritics/RheumaticsBiotechnologyCNS DiseasesInovio PharmaceuticalsNorth AmericaOncologyResearch

OPKO Health to acquire PROLOR Biotech in $480 million stock deal

25-04-2013

Continuing on its acquisitive path, US drugmaker OPKO Health (NYSE: OPK) has signed a definitive agreement…

BiotechnologyMergers & AcquisitionsMetabolicsOPKO HealthPharmaceuticalPROLOR Biotech

OPKO Health acquires 10% stake in Russia's Pharmsynthez

19-04-2013

USA-based OPKO Health (NYSE: OPK) says it has acquired an approximate 10% stake in OAO Pharmsynthez (MICEX:…

EuropeLicensingMarkets & MarketingMergers & AcquisitionsOPKO HealthPharmaceuticalPharmsynthez

RXi Pharma and OPKO Health pooling RNAi assets

08-03-2013

US biotech firm RXi Pharmaceuticals (Nasdaq: RXII) and OPKO Health (NYSE: OPK) have entered into a strategic…

BiotechnologyFinancialLicensingOPKO HealthPharmaceuticalRXi Pharmaceuticals

OPKO Health inks deal to acquire Cytochroma and two Ph III products

10-01-2013

Privately-held Canadian company Cytochroma says that it has entered into a definitive agreement to be…

AlpharenCytochromaMergers & AcquisitionsNephrology and HepatologyOPKO HealthPharmaceuticalReplidea

OPKO Health to acquire Brazil's Silcon to expand Latin American presence

28-12-2012

USA-based OPKO Health (NYSE: OPK) has entered into a definitive agreement to acquire Silcon Comercio,…

Mergers & AcquisitionsOPKO HealthPharmaceuticalSilcon ComercioSouth America

OPKO buys Farmadiet to gain presence in Europe

05-08-2012

Making its third acquisition this year, USA-based OPKO Health (NYSE: OPK) said on Friday that it has…

FarmadietMergers & AcquisitionsOPKO HealthPharmaceutical

OPKO Health to acquire 45% stake in Israeli hepatitis B vaccine maker

06-06-2012

Miami, USA-based OPKO Health (NYSE: OPK) has entered into a definitive agreement to acquire a 45% stake…

FDS PharmaMergers & AcquisitionsOPKO HealthPharmaceuticalSci-B-VacSciGenVaccines

OPKO Health to acquire Chilean drugmaker; buys cancer tests

24-01-2012

Florida, USA-based OPKO Health (NYSE: OPK) had a busy day yesterday, entering into a definitive agreement…

ALS DistribuidoraEuropeMergers & AcquisitionsOPKO HealthPharmaceuticalSouth America

1 to 25 of 26 results

Back to top